Reuters logo
in 2 months
BRIEF-Agilent Technologies, Agendia to develop RNA-SEQ kit version of Agendia's mammaprint, blueprint tests
June 2, 2017 / 3:07 PM / in 2 months

BRIEF-Agilent Technologies, Agendia to develop RNA-SEQ kit version of Agendia's mammaprint, blueprint tests

1 Min Read

June 2 (Reuters) - Agilent Technologies Inc:

* Co, Agendia Inc to expand relationship to develop RNA-SEQ kit version of Agendia's currently marketed mammaprint, blueprint tests

* Agreement accelerates development of tests to assess risk of disease recurrence in women with early-stage breast cancer

* Initial phase of RNA-SEQ kit development is expected to be completed in 2017, providing early access to limited markets in Europe Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below